| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Bacoside A3 targets oxidative stress pathways, exhibiting antioxidant potential. As a triterpenoid saponin, it shows neuroprotective response through decreased intracellular ROS. The compound may have a role in the clinical management of opioid withdrawal induced depression. Its neuroprotective effects suggest interactions with neuronal targets involved in oxidative stress and cell survival. The compound's saponin structure may influence its interactions with cellular membranes and targets. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Bacoside A3 has antioxidant potential and shows neuroprotective response analyzed as higher cell viability and decreased intracellular ROS. The compound shows a newer potential role in the clinical management of opioid withdrawal induced depression. As a triterpenoid saponin, its neuroprotective effects have been characterized. These in vitro findings support its potential applications in neuroprotection and depression research.
|
| ln Vivo |
In vivo studies of Bacoside A3 are limited as the compound is primarily used as a research chemical. Its neuroprotective and antioxidant properties suggest potential for in vivo evaluation in models of neurodegenerative diseases and opioid withdrawal induced depression. However, comprehensive in vivo pharmacological studies specifically targeting Bacoside A3 are not well documented. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for Bacoside A3 typically involve testing its antioxidant activity. Antioxidant activity is assessed using cell-free systems such as DPPH radical scavenging assays. Neuroprotective effects are evaluated in neuronal cell cultures by measuring cell viability and intracellular ROS levels. The compound's purity (≥95%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Bacoside A3 involve culturing neuronal cells to evaluate its neuroprotective effects. Cells are treated with varying concentrations of the compound and exposed to oxidative stress inducers. Cell viability is assessed using MTT or similar colorimetric assays. Intracellular ROS levels are measured using fluorescent probes. For depression research, relevant cell models are used. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Bacoside A3 would be conducted to evaluate its neuroprotective and antidepressant activities. For neuroprotection studies, animals with induced neurodegeneration would be treated and neurological function assessed. For depression studies, animal models of opioid withdrawal induced depression would be used. Parameters assessed would include behavioral outcomes, oxidative stress markers, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Bacoside A3 reflect its nature as a triterpenoid saponin. It has a molecular weight of 929.1 and the molecular formula C47H76O18. The compound appears as a white crystalline powder and has a purity of ≥95%. It is stored at 2-8°C. As a saponin, it has limited oral bioavailability. Complete pharmacokinetic profiling would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Bacoside A3 has been evaluated in the context of its use as a research chemical. As a naturally occurring triterpenoid saponin, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of ≥95%. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Bacoside A3 is a triterpenoid compound. It has been reported that purslane (Bacopa monnieri) contains Bacoside A3, and relevant data are available for reference.
Bacoside A3 (CAS# 157408-08-7) is also known as Absinth A3, Bacopa saponin A3. It has the molecular formula C47H76O18 and a molecular weight of 929.1. The compound is a triterpenoid saponin that appears as a white crystalline powder. Bacoside A3 has antioxidant potential and shows neuroprotective response through higher cell viability and decreased intracellular ROS. It shows potential for clinical management of opioid withdrawal induced depression. The compound has a purity of ≥95%. |
| Molecular Formula |
C47H76O18
|
|---|---|
| Molecular Weight |
929.10
|
| Exact Mass |
928.503
|
| CAS # |
157408-08-7
|
| PubChem CID |
91827005
|
| Appearance |
White to off-white solid
|
| Density |
1.43
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
65
|
| Complexity |
1770
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
O1C([H])([H])[C@@]23C([H])([H])[C@@]41[C@]([H])([C@](C([H])([H])[H])(C([H])([H])[C@]([H])(/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O4)O[H])[C@@]2([H])C([H])([H])C([H])([H])[C@]1([H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(C([H])([H])[H])(C([H])([H])[H])[C@]2([H])C([H])([H])C([H])([H])[C@@]31C([H])([H])[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H]
|
| InChi Key |
CDEVGTJBRPBOPH-INTDMYAHSA-N
|
| InChi Code |
InChI=1S/C47H76O18/c1-21(2)14-22-15-45(7,57)38-23-8-9-28-43(5)12-11-29(42(3,4)27(43)10-13-44(28,6)46(23)19-47(38,65-22)58-20-46)62-41-37(64-39-34(55)31(52)25(17-49)60-39)36(32(53)26(18-50)61-41)63-40-35(56)33(54)30(51)24(16-48)59-40/h14,22-41,48-57H,8-13,15-20H2,1-7H3/t22-,23+,24+,25-,26+,27-,28+,29-,30+,31-,32+,33-,34+,35+,36-,37+,38-,39-,40-,41-,43-,44+,45-,46-,47-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxy-2-(hydroxymethyl)-6-[[(1S,2R,5R,7S,10R,11R,14R,15S,16S,18R,20S)-16-hydroxy-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
Absinth A3; Bacoside A3; Bacopa saponin A3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (107.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0763 mL | 5.3816 mL | 10.7631 mL | |
| 5 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | |
| 10 mM | 0.1076 mL | 0.5382 mL | 1.0763 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
